The global polycystic ovary syndrome (PCOS) market is anticipated to grow at a modest CAGR of around 4.0% during the forecast period (2021-2027). PCOS is an endocrine disorder found in women of childbearing age (ages 15 to 44) which affects their hormone levels. Women with PCOS produce higher-than-normal amounts of male hormones. This hormone imbalance causes their body to skip menstrual periods and makes it harder for them to get pregnant. In PCOS women’s ovaries, the reproductive organs that produce estrogen and progesterone are affected majorly. Diuretics, Insulin Sensitizing Agents, Antiandrogens, and Oral Contraceptive Pills are some of the major drugs used in the diagnosis of PCOD disorder.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/polycystic-ovary-syndrome-pcos-market
The changing lifestyles, rising obesity in women, and increasing cases of hormonal imbalances in women are the factors that contributed to the rise in the incidence of PCOS. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age suffer from the polycystic ovarian syndrome. Additionally, according to the International Journal of Reproduction, Contraception, Obstetrics, and Gynecology, a study was conducted on 170 women of reproductive age, in which 70 women were affected with PCOS which was 41%, in which 16% were married women and 24% in unmarried women with PCOS. Obesity in women is another major factor that increases the chances of PCOS. Thus, the high prevalence is accelerating market growth..
A Full Report of Global Polycystic Ovary Syndrome (PCOS) Market is Available at: https://www.omrglobal.com/industry-reports/polycystic-ovary-syndrome-pcos-market
However, factors such as side effects coupled with PCOS drugs such as weight gain, unwanted hair growth, increase insulin resistance, cardiovascular risks, and thromboembolic events are hindering the growth of the market. Further, the advancements in PCOS is also accelerating the market growth, For instance, in February 2020, Ava, a digital healthcare company focused on women’s reproductive health, announced that it had received clearance approval from FDA for its Ava Fertility Tracker, a wearable fertility tracking sensor bracelet and accompanying app. The device aid women in ovulation prediction and facilitation of conception.
Global Polycystic Ovary Syndrome (PCOS) Market – Company Profiles
- Abbott Laboratories
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Ferring Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Global Polycystic Ovary Syndrome (PCOS) Market- Segmentation
By Drug Type
- Diuretics
- Insulin Sensitizing Agents
- Antiandrogens
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Anti-Obesity
- Oral Contraceptive Pills
By Diagnosis Type
- Ultrasound
- Pelvic Exam
- Blood Test
Global Polycystic Ovary Syndrome (PCOS) Market- Regions
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/polycystic-ovary-syndrome-pcos-market
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
